Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s00268-013-1970-4
Title: | Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial | Authors: | Chung, A.Y.F. Ooi, L.L.P.J. Machin, D. Tan, S.B. Goh, B.K.P. Wong, J.S. Chen, Y.M. Li, P.C.N. Gandhi, M. Thng, C.H. Yu, S.W.K. Tan, B.S. Lo, R.H.G. Htoo, A.M.M. Tay, K.H. Sundram, F.X. Goh, A.S.W. Chew, S.P. Liau, K.H. Chow, P.K.H. Tay, K.H. Tan, Y.M. Cheow, P.C. Ho, C.K. Soo, K.C. |
Issue Date: | Jun-2013 | Citation: | Chung, A.Y.F., Ooi, L.L.P.J., Machin, D., Tan, S.B., Goh, B.K.P., Wong, J.S., Chen, Y.M., Li, P.C.N., Gandhi, M., Thng, C.H., Yu, S.W.K., Tan, B.S., Lo, R.H.G., Htoo, A.M.M., Tay, K.H., Sundram, F.X., Goh, A.S.W., Chew, S.P., Liau, K.H., Chow, P.K.H., Tay, K.H., Tan, Y.M., Cheow, P.C., Ho, C.K., Soo, K.C. (2013-06). Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial. World Journal of Surgery 37 (6) : 1356-1361. ScholarBank@NUS Repository. https://doi.org/10.1007/s00268-013-1970-4 | Abstract: | Background: The purpose of the present study was to determine whether intrahepatic injection of 131I-lipiodol (Lipiodol) is effective against recurrence of surgically resected hepatocellular carcinoma (HCC). Methods: From June 2001 through March 2007, this nationwide multi-center prospective randomized controlled trial enrolled 103 patients 4-6 weeks after curative resection of HCC with complete recovery (52: Lipiodol, 51: Control). Follow-up was every 3 months for 1 year, then every 6 months. Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively, both of which were evaluated by the Kaplan-Meier technique and summarized by the hazard ratio (HR). The design was based on information obtained from a similar trial that had been conducted in Hong Kong. Results: The Lipiodol group showed a small, and nonsignificant, improvement over control in RFS (HR = 0.75; 95 % confidence interval [95 % CI] 0.46-1.23; p = 0.25) and OS (HR = 0.88; 95 % CI 0.51-1.51; p = 0.64). Only two serious adverse events were reported, both with hypothyroidism caused by 131I-lipiodol and hepatic artery dissection during angiography. Conclusions: The randomized trial provides insufficient evidence to recommend the routine use of 131I-lipiodol in these patients. © 2013 Société Internationale de Chirurgie. | Source Title: | World Journal of Surgery | URI: | http://scholarbank.nus.edu.sg/handle/10635/108841 | ISSN: | 03642313 | DOI: | 10.1007/s00268-013-1970-4 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.